PK/PD
- General Concepts and Advanced Material - ADVANCED LEVEL |
PK/PD Modeling Methods and Clinical Applications (Intermediate - Advanced - Expert Level) |
|
Faculty: Roger Jelliffe, MD |
Target
Participants:
This
workshop, using minimal math, starts at a beginning level and progresses
to an advanced level over 2 intensive days. It is intended for physicians,
pharmacists, clinical chemists and biomedical scientists who have an interest
in clinical therapeutic drug monitoring and optimal individualization of
drug therapy for patient care and in population pharmacokinetic and pharmacodynamic
research modeling techniques. Participants will be introduced to the USC*PACK
software which can be used both for therapeutic drug monitoring as well
as for parametric and nonparametric population PK/PD and physiological modeling.
|
Objectives and Expectations: After this workshop, the participant should: |
1. | Be able
to describe basic pharmacokinetic behavior of drugs in patients. |
2. | Be able to design optimal initial individualized dosage regimens of drugs to hit selected target goals most precisely. |
3. | Be able to enter and store patient data of doses, TDM serum concentrations, etc., and to make an individualized model of drug behavior in that patient. |
4. | Be able to develop an adjusted dosage regimen based on the patient's individualized model. |
5. | Understand how to apply these techniques to therapy with vancomycin, digoxin, anticonvulsants, and drugs for AIDS, cancer, and transplants. |
6. | Understand the basic ideas (not the math) behind parametric and nonparametric population PK/PD modeling. |
7. | Know how to determine the error polynomial for a drug assay, to fit each data point by an optimal measure of its credibility. |
8. | Understand Monte-Carlo simulation and its applications to clinical situations. |
9. | Understand the basic concepts of multiple model dosage design. |
PK/PD Modeling Methods and Clinical Applications (Intermediate - Advanced - Expert Level) |
Tuesday,
September 07th, 2004 |
Preliminary Program
Time
|
Topic |
8:30 |
Beginning-Intermediate
Clinical PK 1
The basic PK model – Roger Jelliffe Dose individualization using target concentration
strategy An
example for discussion: tracking drug behavior in unstable patients, with Basic PK building blocks
Evaluating renal function, especially in unstable patients |
9:30 |
Beginning-Intermediate Clinical PK 2Ways of fitting data - Roger Jelliffe |
10:30 |
Coffee |
11:00 |
Beginning-Intermediate
Population Modeling
Parametric, iterative 2 stage Bayesian (IT2B) population modeling - Roger Jelliffe |
11:45 |
Nonparametric Population Modeling - Roger Jelliffe
Its
strengths and weaknesses |
12:30 |
Multiple
Model Dosage Design - Roger Jelliffe
|
13:00 |
Lunch |
14:30 |
Intermediate PK – Tissue Distribution Modeling diffusion in endocardial vegetations - Roger Jelliffe |
15:30 |
How to describe and build PD relationships for anti-infective
drugs - George Drusano
|
16:00 |
Erythropoetin therapy in childhood renal anemia - Rüdiger Port |
16:30 |
End |
PK/PD Modeling Methods and Clinical Applications (Intermediate - Advanced - Expert Level) |
Wednesday,
September 08th, 2004 |
Preliminary Program
Time
|
Topic |
8:30 |
Advanced
PK 3
Modeling
linear and nonlinear antiepileptic drug models - Irina Bondareva |
9:00 |
Outcome and costs
of a goal-oriented, model-based, active TDM service – Alexander Vinks |
9:45 |
Combination chemotherapy
- Monte-Carlo simulation: from PK/PD
Relationships to clinical applications - George Drusano |
10:30 |
Coffee |
11:00 |
Applied Clinical
PK 4 Getting Nonparametric
Bayesian Posteriors – Roger
Jelliffe The structure of MM Bayesian dosage
individualization and adjustment |
12:00 |
Aminoglycoside ototoxicity -
Roger Jelliffe |
12:30 |
Introduction
to Clinical Cases - Roger Jelliffe
Planning initial MM aminoglycoside
therapy |
13:00 |
Lunch |
14:30 |
Advanced Clinical
PK 5 More clinical case
histories - Roger Jelliffe |
16:30 |
End |
Link to the PK/PD General Concepts program at the beginner - intermediate level